Cover storyExplore how pharma leaders can build governed AI systems that improve manufacturing without compromising quality or accountability.
Alcon's Brytly becomes the first nonprescription apraclonidine eye drop approved by FDA, signaling continued agency push on OTC drug access.
FDA confirms bacterial contamination in counterfeit eye drops from DLC Laboratories, ProMex, and Laboratorios Sophia found across six U.S. states.
EMA's CHMP issued six positive opinions in October 2026, including oral GLP-1 orforglipron and two biosimilars, with key implications for EU market entry.
Adial Pharmaceuticals names tapinarof architect David Rubenstein as Chief Scientist to lead AT177 through IND-enabling studies toward 2027 first-in-human trials.
Latest edition
Interview
Interview
Interview
Podcast
SPONSORED
SPONSORED
SPONSORED
Oct 20
Oct 28
Nov 18From native content to event partnerships, we help brands earn the attention of a hard-to-reach, senior audience — without breaking the reading experience.
See partnership options →Explore expert-led guides crafted for pharma professionals. Log in to download and stay ahead.
Join thousands of pharma professionals getting our sharpest reporting, briefings and guides — free.
